Lakefront Biotherapeutics American Depositary Shares (LKFT) Competitors

$27.49 -0.65 (-2.31%)

As of 04:00 PM Eastern

LKFT vs. QGEN, KYMR, ACLX, MIRM, and PTGX

Should you buy Lakefront Biotherapeutics American Depositary Shares stock or one of its competitors? MarketBeat compares Lakefront Biotherapeutics American Depositary Shares with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lakefront Biotherapeutics American Depositary Shares include Qiagen (QGEN), Kymera Therapeutics (KYMR), Arcellx (ACLX), Mirum Pharmaceuticals (MIRM), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry.

How does Lakefront Biotherapeutics American Depositary Shares compare to Qiagen?

Qiagen (NYSE:QGEN) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Qiagen has higher revenue and earnings than Lakefront Biotherapeutics American Depositary Shares. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.10B	3.27	$424.88M	$1.91	17.44
Lakefront Biotherapeutics American Depositary Shares	$1.04B	1.74	$363.05M	-$1.41	N/A

Qiagen has a net margin of 19.16% compared to Lakefront Biotherapeutics American Depositary Shares' net margin of 0.00%. Qiagen's return on equity of 14.40% beat Lakefront Biotherapeutics American Depositary Shares' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.16%	14.40%	8.40%
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A

Qiagen has a beta of 0.64, suggesting that its share price is 36% less volatile than the broader market. Comparatively, Lakefront Biotherapeutics American Depositary Shares has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market.

70.0% of Qiagen shares are held by institutional investors. Comparatively, 32.5% of Lakefront Biotherapeutics American Depositary Shares shares are held by institutional investors. 9.0% of Qiagen shares are held by company insiders. Comparatively, 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Qiagen presently has a consensus target price of $46.38, suggesting a potential upside of 39.25%. Lakefront Biotherapeutics American Depositary Shares has a consensus target price of $36.50, suggesting a potential upside of 32.78%. Given Qiagen's stronger consensus rating and higher possible upside, equities research analysts clearly believe Qiagen is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	0 Sell rating(s)	7 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50
Lakefront Biotherapeutics American Depositary Shares	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00

In the previous week, Qiagen had 9 more articles in the media than Lakefront Biotherapeutics American Depositary Shares. MarketBeat recorded 13 mentions for Qiagen and 4 mentions for Lakefront Biotherapeutics American Depositary Shares. Qiagen's average media sentiment score of 0.23 beat Lakefront Biotherapeutics American Depositary Shares' score of 0.14 indicating that Qiagen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	2 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Lakefront Biotherapeutics American Depositary Shares	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Qiagen beats Lakefront Biotherapeutics American Depositary Shares on 16 of the 16 factors compared between the two stocks.

How does Lakefront Biotherapeutics American Depositary Shares compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and media sentiment.

In the previous week, Kymera Therapeutics had 4 more articles in the media than Lakefront Biotherapeutics American Depositary Shares. MarketBeat recorded 8 mentions for Kymera Therapeutics and 4 mentions for Lakefront Biotherapeutics American Depositary Shares. Kymera Therapeutics' average media sentiment score of 0.32 beat Lakefront Biotherapeutics American Depositary Shares' score of 0.14 indicating that Kymera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lakefront Biotherapeutics American Depositary Shares	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kymera Therapeutics presently has a consensus target price of $118.10, indicating a potential upside of 39.76%. Lakefront Biotherapeutics American Depositary Shares has a consensus target price of $36.50, indicating a potential upside of 32.78%. Given Kymera Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Kymera Therapeutics is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.96
Lakefront Biotherapeutics American Depositary Shares	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00

Kymera Therapeutics has a beta of 2.06, indicating that its share price is 106% more volatile than the broader market. Comparatively, Lakefront Biotherapeutics American Depositary Shares has a beta of 0.25, indicating that its share price is 75% less volatile than the broader market.

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Lakefront Biotherapeutics American Depositary Shares, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	177.28	-$311.35M	-$3.57	N/A
Lakefront Biotherapeutics American Depositary Shares	$1.04B	1.74	$363.05M	-$1.41	N/A

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are held by institutional investors. 16.0% of Kymera Therapeutics shares are held by company insiders. Comparatively, 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Lakefront Biotherapeutics American Depositary Shares has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -611.94%. Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-611.94%	-24.71%	-22.05%
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A

Summary

Kymera Therapeutics and Lakefront Biotherapeutics American Depositary Shares tied by winning 8 of the 16 factors compared between the two stocks.

How does Lakefront Biotherapeutics American Depositary Shares compare to Arcellx?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and Arcellx (NASDAQ:ACLX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

Lakefront Biotherapeutics American Depositary Shares has a net margin of 0.00% compared to Arcellx's net margin of -1,027.26%. Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Arcellx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
Arcellx	-1,027.26%	-55.42%	-36.24%

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Arcellx. Arcellx is trading at a lower price-to-earnings ratio than Lakefront Biotherapeutics American Depositary Shares, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$1.04B	1.74	$363.05M	-$1.41	N/A
Arcellx	$22.29M	301.95	-$228.93M	-$4.07	N/A

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.25, meaning that its share price is 75% less volatile than the broader market. Comparatively, Arcellx has a beta of 0.25, meaning that its share price is 75% less volatile than the broader market.

In the previous week, Lakefront Biotherapeutics American Depositary Shares had 4 more articles in the media than Arcellx. MarketBeat recorded 4 mentions for Lakefront Biotherapeutics American Depositary Shares and 0 mentions for Arcellx. Arcellx's average media sentiment score of 1.07 beat Lakefront Biotherapeutics American Depositary Shares' score of 0.14 indicating that Arcellx is being referred to more favorably in the news media.

Company	Overall Sentiment
Lakefront Biotherapeutics American Depositary Shares	Neutral
Arcellx	Positive

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are held by institutional investors. Comparatively, 96.0% of Arcellx shares are held by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are held by company insiders. Comparatively, 8.4% of Arcellx shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Lakefront Biotherapeutics American Depositary Shares currently has a consensus target price of $36.50, indicating a potential upside of 32.78%. Arcellx has a consensus target price of $111.87, indicating a potential downside of 2.78%. Given Lakefront Biotherapeutics American Depositary Shares' higher probable upside, analysts plainly believe Lakefront Biotherapeutics American Depositary Shares is more favorable than Arcellx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00
Arcellx	1 Sell rating(s)	16 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.11

Summary

Lakefront Biotherapeutics American Depositary Shares beats Arcellx on 9 of the 15 factors compared between the two stocks.

How does Lakefront Biotherapeutics American Depositary Shares compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

Mirum Pharmaceuticals currently has a consensus price target of $136.42, indicating a potential upside of 22.47%. Lakefront Biotherapeutics American Depositary Shares has a consensus price target of $36.50, indicating a potential upside of 32.78%. Given Lakefront Biotherapeutics American Depositary Shares' higher probable upside, analysts clearly believe Lakefront Biotherapeutics American Depositary Shares is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93
Lakefront Biotherapeutics American Depositary Shares	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00

Mirum Pharmaceuticals has a beta of 0.52, meaning that its stock price is 48% less volatile than the broader market. Comparatively, Lakefront Biotherapeutics American Depositary Shares has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market.

Lakefront Biotherapeutics American Depositary Shares has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -140.24%. Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Mirum Pharmaceuticals. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	13.03	-$23.36M	-$13.61	N/A
Lakefront Biotherapeutics American Depositary Shares	$1.04B	1.74	$363.05M	-$1.41	N/A

In the previous week, Mirum Pharmaceuticals had 20 more articles in the media than Lakefront Biotherapeutics American Depositary Shares. MarketBeat recorded 24 mentions for Mirum Pharmaceuticals and 4 mentions for Lakefront Biotherapeutics American Depositary Shares. Mirum Pharmaceuticals' average media sentiment score of 0.67 beat Lakefront Biotherapeutics American Depositary Shares' score of 0.14 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	6 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Lakefront Biotherapeutics American Depositary Shares	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. 14.4% of Mirum Pharmaceuticals shares are owned by company insiders. Comparatively, 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Mirum Pharmaceuticals and Lakefront Biotherapeutics American Depositary Shares tied by winning 8 of the 16 factors compared between the two stocks.

How does Lakefront Biotherapeutics American Depositary Shares compare to Protagonist Therapeutics?

Protagonist Therapeutics (NASDAQ:PTGX) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.

Protagonist Therapeutics currently has a consensus price target of $113.69, indicating a potential upside of 7.71%. Lakefront Biotherapeutics American Depositary Shares has a consensus price target of $36.50, indicating a potential upside of 32.78%. Given Lakefront Biotherapeutics American Depositary Shares' higher possible upside, analysts plainly believe Lakefront Biotherapeutics American Depositary Shares is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Lakefront Biotherapeutics American Depositary Shares	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00

Protagonist Therapeutics has a beta of 1.89, indicating that its stock price is 89% more volatile than the broader market. Comparatively, Lakefront Biotherapeutics American Depositary Shares has a beta of 0.25, indicating that its stock price is 75% less volatile than the broader market.

In the previous week, Protagonist Therapeutics had 10 more articles in the media than Lakefront Biotherapeutics American Depositary Shares. MarketBeat recorded 14 mentions for Protagonist Therapeutics and 4 mentions for Lakefront Biotherapeutics American Depositary Shares. Lakefront Biotherapeutics American Depositary Shares' average media sentiment score of 0.14 beat Protagonist Therapeutics' score of 0.10 indicating that Lakefront Biotherapeutics American Depositary Shares is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lakefront Biotherapeutics American Depositary Shares	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Protagonist Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Lakefront Biotherapeutics American Depositary Shares, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$74.06M	91.65	-$130.15M	-$1.81	N/A
Lakefront Biotherapeutics American Depositary Shares	$1.04B	1.74	$363.05M	-$1.41	N/A

98.6% of Protagonist Therapeutics shares are held by institutional investors. Comparatively, 32.5% of Lakefront Biotherapeutics American Depositary Shares shares are held by institutional investors. 5.2% of Protagonist Therapeutics shares are held by company insiders. Comparatively, 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Lakefront Biotherapeutics American Depositary Shares has a net margin of 0.00% compared to Protagonist Therapeutics' net margin of -154.88%. Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Protagonist Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A

Summary

Lakefront Biotherapeutics American Depositary Shares beats Protagonist Therapeutics on 10 of the 17 factors compared between the two stocks.

Get Lakefront Biotherapeutics American Depositary Shares News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LKFT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LKFT vs. The Competition

Export

Metric	Lakefront Biotherapeutics American Depositary Shares	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.81B	$3.40B	$6.29B	$12.46B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	-19.50	18.81	20.87	25.61
Price / Sales	1.74	181.76	521.62	63.45
Price / Cash	37.64	122.51	42.94	55.34
Price / Book	0.48	6.75	9.86	6.71
Net Income	$363.05M	$24.11M	$3.55B	$333.77M
7 Day Performance	-0.87%	0.11%	-0.26%	0.40%
1 Month Performance	-4.81%	0.87%	1.39%	4.03%
1 Year Performance	3.74%	78.18%	41.07%	36.33%

Lakefront Biotherapeutics American Depositary Shares Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LKFT Lakefront Biotherapeutics American Depositary Shares	2.8284 of 5 stars	$27.49 -2.3%	$36.50 +32.8%	+4.8%	$1.81B	$1.04B	N/A	1,310
QGEN Qiagen	4.5752 of 5 stars	$33.91 -0.1%	$47.09 +38.9%	-26.1%	$6.99B	$2.09B	16.82	5,654	Earnings Report Dividend Increase Analyst Downgrade
KYMR Kymera Therapeutics	2.3817 of 5 stars	$82.87 -0.9%	$118.70 +43.2%	+174.9%	$6.86B	$39.21M	N/A	170	Insider Trade
ACLX Arcellx	2.5092 of 5 stars	$115.07 flat	$111.87 -2.8%	+97.5%	$6.73B	$22.29M	N/A	80	High Trading Volume
MIRM Mirum Pharmaceuticals	2.4837 of 5 stars	$108.69 +2.7%	$125.25 +15.2%	+141.1%	$6.61B	$521.31M	N/A	140	Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LKFT) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lakefront Biotherapeutics American Depositary Shares (LKFT) Competitors

LKFT vs. QGEN, KYMR, ACLX, MIRM, and PTGX

How does Lakefront Biotherapeutics American Depositary Shares compare to Qiagen?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Kymera Therapeutics?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Arcellx?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Mirum Pharmaceuticals?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Protagonist Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LKFT vs. The Competition

Lakefront Biotherapeutics American Depositary Shares Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lakefront Biotherapeutics American Depositary Shares (LKFT) Competitors

LKFT vs. QGEN, KYMR, ACLX, MIRM, and PTGX

How does Lakefront Biotherapeutics American Depositary Shares compare to Qiagen?

Which has better earnings and valuation, QGEN or LKFT?

Is QGEN or LKFT more profitable?

Which has more risk & volatility, QGEN or LKFT?

Do insiders and institutionals hold more shares of QGEN or LKFT?

Do analysts prefer QGEN or LKFT?

Does the media favor QGEN or LKFT?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Kymera Therapeutics?

Does the media favor KYMR or LKFT?

Do analysts rate KYMR or LKFT?

Which has more volatility and risk, KYMR or LKFT?

Which has better valuation & earnings, KYMR or LKFT?

Do institutionals & insiders believe in KYMR or LKFT?

Is KYMR or LKFT more profitable?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Arcellx?

Is LKFT or ACLX more profitable?

Which has higher valuation and earnings, LKFT or ACLX?

Which has more volatility and risk, LKFT or ACLX?

Does the media prefer LKFT or ACLX?

Do insiders and institutionals hold more shares of LKFT or ACLX?

Do analysts recommend LKFT or ACLX?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Mirum Pharmaceuticals?

Do analysts recommend MIRM or LKFT?

Which has more volatility & risk, MIRM or LKFT?

Is MIRM or LKFT more profitable?

Which has stronger valuation & earnings, MIRM or LKFT?

Does the media prefer MIRM or LKFT?

Do institutionals and insiders believe in MIRM or LKFT?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Protagonist Therapeutics?

Do analysts rate PTGX or LKFT?

Which has more risk and volatility, PTGX or LKFT?

Does the media prefer PTGX or LKFT?

Which has better valuation & earnings, PTGX or LKFT?

Do institutionals and insiders hold more shares of PTGX or LKFT?

Is PTGX or LKFT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LKFT vs. The Competition

Lakefront Biotherapeutics American Depositary Shares Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools